ENTA logo

ENANTA PHARMACEUTICALS INC

ENTANASDAQ
🏆 #3213 by market capEarnings Nov 16 · PostUS Equity
$12.64▼ $0.01 (−0.04%)
Market closed · at close
🔔
Track ENTA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.0%
7d▲ 5.7%
14d▼ 0.7%
30d▼ 5.0%
ytd▼ 20.3%
1y▲ 5.5%
🏦Market Cap
$368M
Small Cap
📈Revenue Growth (YoY)
-3.4%
Declining
📊Gross Margin
98.2%
High
💵FCF Margin
-56.6%
Thin
⚖️P/S Ratio
5.6x
Fair
Otter Score
68
Fair

Trading Snapshot

Day Range
$12.54 – $12.85
52-Week Range
$7.05 – $17.15
Volume
$3.97B
Avg Volume
$5.12B
Shares Outstanding
29.1M
Next Earnings
Oct 19, 2026

Fundamentals Snapshot

Annual Revenue
$65M
Last Q Revenue
$14M
P/E Ratio
-5.2
P/S Ratio
5.6x
EPS (TTM)
$-2.17
Dividend Yield
0.00%
Dilution (1yr)
+35.4%

Why Investors Own ENTA

  • ✓High-growth profile — revenue up +40.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 54% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ENTA logo

ENANTA PHARMACEUTICALS INC

ENTA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$65M▼ −3.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
93.0%▼ −7.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$85M▼ −29.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$32M▼ −66.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
28.7M▲ +35.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$156M▼ −$19M YoY
StockOtter · stockotter.space

About ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Ratings

ⓘ
Consensus
Buy
12 analysts
Strong Buy4
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Barron’s·2h ago

ENANTA PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift ENTA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

ENANTA PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.